tetano
Editor, Senior Moderator
J Infect Dis
. 2024 Sep 3:jiae400.
doi: 10.1093/infdis/jiae400. Online ahead of print. Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Holly Janes[SUP] 1 [/SUP], Leigh H Fisher[SUP] 1 [/SUP], Jia Jin Kee[SUP] 1 [/SUP], Lalitha Parameswaran[SUP] 2 [/SUP], Paul A Goepfert[SUP] 3 [/SUP], Ann R Falsey[SUP] 4 [/SUP], James Ludwig[SUP] 1 [/SUP], Craig A Magaret[SUP] 1 [/SUP], Peter B Gilbert[SUP] 1 [/SUP], James G Kublin[SUP] 1 [/SUP], Nadine Rouphael[SUP] 5 [/SUP], Magdalena E Sobieszczyk[SUP] 6 [/SUP], Hana M El Sahly[SUP] 7 [/SUP], Lindsey R Baden[SUP] 8 [/SUP], Beatriz Grinsztejn[SUP] 9 [/SUP], Stephen R Walsh[SUP] 8 [/SUP], Glenda E Gray[SUP] 10 [/SUP], Karen L Kotloff[SUP] 11 [/SUP], Cynthia L Gay[SUP] 12 [/SUP], Alexander L Greninger[SUP] 13 [/SUP], Milagritos D Tapia[SUP] 11 [/SUP], E Adrianne Hammershaimb[SUP] 11 [/SUP], Frances H Priddy[SUP] 14 [/SUP], Justin A Green[SUP] 15 [/SUP], Frank Struyf[SUP] 16 [/SUP], Lisa Dunkle[SUP] 17 [/SUP], Kathleen M Neuzil[SUP] 18 [/SUP], Lawrence Corey[SUP] 1 [/SUP], Yunda Huang[SUP] 1 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38-4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44-2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, -.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, -.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated. Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802.
Keywords: COVID-19 transmission; COVID-19 vaccine; SARS-CoV-2 viral load; infectiousness; randomized trial.
. 2024 Sep 3:jiae400.
doi: 10.1093/infdis/jiae400. Online ahead of print. Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Holly Janes[SUP] 1 [/SUP], Leigh H Fisher[SUP] 1 [/SUP], Jia Jin Kee[SUP] 1 [/SUP], Lalitha Parameswaran[SUP] 2 [/SUP], Paul A Goepfert[SUP] 3 [/SUP], Ann R Falsey[SUP] 4 [/SUP], James Ludwig[SUP] 1 [/SUP], Craig A Magaret[SUP] 1 [/SUP], Peter B Gilbert[SUP] 1 [/SUP], James G Kublin[SUP] 1 [/SUP], Nadine Rouphael[SUP] 5 [/SUP], Magdalena E Sobieszczyk[SUP] 6 [/SUP], Hana M El Sahly[SUP] 7 [/SUP], Lindsey R Baden[SUP] 8 [/SUP], Beatriz Grinsztejn[SUP] 9 [/SUP], Stephen R Walsh[SUP] 8 [/SUP], Glenda E Gray[SUP] 10 [/SUP], Karen L Kotloff[SUP] 11 [/SUP], Cynthia L Gay[SUP] 12 [/SUP], Alexander L Greninger[SUP] 13 [/SUP], Milagritos D Tapia[SUP] 11 [/SUP], E Adrianne Hammershaimb[SUP] 11 [/SUP], Frances H Priddy[SUP] 14 [/SUP], Justin A Green[SUP] 15 [/SUP], Frank Struyf[SUP] 16 [/SUP], Lisa Dunkle[SUP] 17 [/SUP], Kathleen M Neuzil[SUP] 18 [/SUP], Lawrence Corey[SUP] 1 [/SUP], Yunda Huang[SUP] 1 [/SUP]
Affiliations
- PMID: 39225478
- DOI: 10.1093/infdis/jiae400
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38-4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44-2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, -.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, -.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated. Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802.
Keywords: COVID-19 transmission; COVID-19 vaccine; SARS-CoV-2 viral load; infectiousness; randomized trial.